Verily Life Sciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

verily.com

Founded Year

2015

Stage

Private Equity - II | Alive

Total Raised

$2.5B

Last Raised

$700M | 2 yrs ago

Mosaic Score

+30 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Verily Life Sciences

Verily Life Sciences develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. The company partners with leading life sciences, medical device and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale.

Verily Life Sciences Headquarter Location

269 E Grand Ave

South San Francisco, California, 94080,

United States

650-253-0000

ESPs containing Verily Life Sciences

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Medical Devices Tech

Bioelectronic neuromodulators alleviate symptoms and treat diseases by targeting and manipulating (with electrical currents) specific electrical circuits in the body. This approach has a broad array of applications — from spinal cord stimulation for pain relief to tibial nerve stimulation for overactive bladders to vagus nerve stimulation for seizure prevention.

Verily Life Sciences named as Leader among 10 other companies, including Stimdia Medical, Cala Health, and Neuspera Medical.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Verily Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verily Life Sciences is included in 9 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

S

Sleep Health & Wellness

801 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

M

Medical Devices

12,390 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

D

Diabetes

1,750 items

D

Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

T

Telehealth

2,833 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Verily Life Sciences Patents

Verily Life Sciences has filed 869 patents.

The 3 most popular patent topics include:

  • Ophthalmology
  • Sensors
  • Diabetes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/28/2019

8/9/2022

Neurotechnology, Implants (medicine), Neurological disorders, Neurophysiology, Electrotherapy

Grant

Application Date

8/28/2019

Grant Date

8/9/2022

Title

Related Topics

Neurotechnology, Implants (medicine), Neurological disorders, Neurophysiology, Electrotherapy

Status

Grant

Latest Verily Life Sciences News

Partnership launches no-cost wastewater monitoring service for local governments

Aug 5, 2022

Partnership launches no-cost wastewater monitoring service for local governments Written by Andy Castillo 5th August 2022 Of all the important lessons cities and counties have learned since the pandemic began, high up on the list is the value of working together. No one community can solve cross-jurisdictional challenges alone—that’s a concept that’s at the heart of a new initiative launched by the National League of Cities (NLC) and WastewaterSCAN that brings no-cost wastewater monitoring services to local governments. “This partnership’s work to expand access to wastewater monitoring tools and analysis will help cities, towns and villages across the country lead their response efforts to the monkeypox outbreak equipped with data and a network of support,” said Clarence Anthony, NLC’s CEO and executive director in a statement about the project. The collaborative will bring together scientists from Stanford University, Emory University, and the life sciences company Verily Life Sciences to monitor, detect viral genetic material, and respond to diseases like COVID-19, monkeypox, influenza and respiratory syncytial virus. Once identified, WastewaterSCAN will provide participating communities with information about their wastewater levels and help them shape public health responses. A statement from NLC notes that 38 treatment plants in eight states are currently receiving monkeypox results from WastewaterSCAN and SCAN in addition to results for the SARS-CoV-2 virus that causes COVID-19 and its variants, among other things. Wastewater monitoring is an important aspect of tracking public health, so the project and its implications is notable for administrators. “Because it’s population-based and unbiased by access to clinical testing, wastewater helps us know the magnitude of an infectious disease in parts of a community. We know how valuable this can be, as testing practices for SARS-CoV-2 have changed,” said Alexandria Boehm, a Stanford University professor of civil and environmental engineering, in a statement about the project. “Genetic material of the pathogens we monitor has been documented in excretions from infected people that end up in the wastewater treatment system.” An information brief on the project notes that “Wastewater data will be analyzed, and results provided to participating cities within 48 hours of wastewater sample arrivals at Verily, the lab partner for WastewaterSCAN. Wastewater monitoring results will be posted on the WastewaterSCAN website along with those of other participating cities. The project’s aim is to arm communities with wastewater data to inform public health planning and decision-making for addressing COVID-19, influenza, monkeypox and RSV and, in the long term, in preparing for the risks from other pathogens. After a year, NLC will release a report on best practices for city administrators. The initiative is open to cities and towns that serve a sewer shed district of 50,000 people or more . Participating cities r eceive free test kits to draw water samples three times per week, access to a data dashboard where results are posted, and virtual learning opportunities that include interactive sessions with subject matter experts. Interested cities can apply to the Wastewater Monitoring Initiative on NLC’s website. The deadline to apply is Sept. 2, and after that, applications will be accepted on a rolling basis.

Verily Life Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Verily Life Sciences Rank

  • When was Verily Life Sciences founded?

    Verily Life Sciences was founded in 2015.

  • Where is Verily Life Sciences's headquarters?

    Verily Life Sciences's headquarters is located at 269 E Grand Ave, South San Francisco.

  • What is Verily Life Sciences's latest funding round?

    Verily Life Sciences's latest funding round is Private Equity - II.

  • How much did Verily Life Sciences raise?

    Verily Life Sciences raised a total of $2.5B.

  • Who are the investors of Verily Life Sciences?

    Investors of Verily Life Sciences include Temasek, Silver Lake, Alphabet, Ontario Teachers' Pension Plan and X - The Moonshot Factory.

  • Who are Verily Life Sciences's competitors?

    Competitors of Verily Life Sciences include Diameter Health, Orchestra BioMed, Stimdia Medical, Digital Diagnostics, Cala Health, Lungpacer Medical, Clareto, Huma, Health Gorilla, Saluda Medical and 51 more.

You May Also Like

Cardionomic Logo
Cardionomic

Cardionomic addresses Acute Decompensated Heart Failure's root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality.

N
Neuspera Medical

Neuspera Medical is a medical device startup that leverages exclusively licensed mid-field powering techniques to engineer miniaturized injectable neuromodulation technologies, sometimes referred to as electroceuticals. Neuspera's implantable module is more than 100 times smaller than other neuromodulation devices and may substantially reduce implant procedure complexity, time, patient complication, and post-surgical pain. Neuspera Medical is committed to bringing forward implantable medical device technology that will improve lives of patients battling with chronic illness.

S
ShiraTronics

ShiraTronics develops an approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical is developing a bioelectronic medicine platform using a small implanted device that activates the body's natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.

L
LivaNova

LivaNova is a medical device company in the treatment of cardiovascular diseases. The company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.

B
Brainsgate

BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.